Citeline and Norstella have completed a merger, first announced in June, to create one of the largest players in the pharmaceutical intelligence category.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh